Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Sumitomo Pharma Co., Ltd.

https://www.sumitomo-pharma.com/

Latest From Sumitomo Pharma Co., Ltd.

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Bookmark
  • Interviews
By Andrew McConaghie

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Companies Financing

Europe’s Biotech Sector Still In Reasonable Shape

Bookmark
  • Analysis
By Kevin Grogan

Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.

Financing C-Suite Speaks

Finance Watch: Gilde Closes Sixth Venture Fund With €740m For Drugs, MedTech

Bookmark
  • News
By Mandy Jackson

Private Company Edition: The €740m ($806.5m) Gilde Healthcare Venture&Growth VI Fund will back companies in Europe and North America. Among recent financings, VectorY raised a €129m ($138m) series A round, EyeBio expanded its series A to $130m and MBrace raised an $85m series B.

Finance Watch StartUps and SMEs

Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets

Bookmark
  • News
By Joseph Haas

Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Adagio Pharmaceuticals Ltd.
    • Altavant Sciences
    • Boston Biomedical, Inc.
    • Boston Biomedical Pharma, Inc.
    • Cannasat Therapeutics Inc.
    • Cynapsus Therapeutics, Inc.
    • Dainippon Sumitomo Pharma Co., Ltd.
    • Dainippon Sumitomo Pharma Europe Ltd.
    • DS Pharma Promo Co., Ltd,
    • Elevation Pharmaceuticals, Inc.
    • Enzyvant Therapeutics, Inc.
    • Enzyvant Sciences, Ltd.
    • Myovant Sciences Ltd
    • Myovant Sciences GmbH
    • Myovant Sciences, Inc.
    • Oryx Pharmaceuticals Inc.
    • SB Bioscience Co., Ltd.
    • Spirovant Sciences
    • Sumitomo Chemical Co., Ltd.
    • Sumitomo Dainippon Pharma America, Inc. (formerly Dainippon Sumitomo Pharma America Holdings, Inc.)
    • Sumitomo Dainippon Pharma Oncology, Inc.
    • Sumitomo Pharmaceuticals America
    • Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
    • Sumitovant Biopharma
    • Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.)
    • Sunovion Pharmaceuticals Europe Ltd.
    • Sunovion Respiratory Development Inc.
    • Tolero Pharmaceuticals, Inc.
    • Urovant Sciences, Inc.
    • Sumitomo Pharmaceuticals Taiwan Co., Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By